(Q34453423)

2 August 2017

title

The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective (English)

1 reference

2 August 2017

0 references

0 references

0 references

Laughren TP

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

16

1 reference

2 August 2017

issue

7

1 reference

2 August 2017

page(s)

418-423

1 reference

Consistency of atypical antipsychotic superiority to placebo in recent clinical trials

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2801%2900600-9

7 January 2021

Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2801%2900600-9

7 January 2021

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2801%2900600-9

7 January 2021

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2801%2900600-9

7 January 2021

The continuing unethical use of placebo controls

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2801%2900600-9

7 January 2021

10.1016/S0924-9338(01)00600-9

Identifiers

DOI

1 reference

2 August 2017

1 reference